Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodThe Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis

Acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity (Ph+) has a poor prognosis historically, so allogeneic hematopoietic cell transplantation (allo-HCT) is advised after the first complete remission (CR1). The rapid achievement of a complete molecular remission (CMR), however, is associated with excellent outcomes without allo-HCT in the tyrosine kinase inhibitor (TKI) era, indicating transplant may not be necessary for these patients. To test this theory, the authors of this journal-based CME program looked into 5 transplant centers in the US to find adult Ph+ ALL patients who received induction therapy, such as TKIs, and received CMR within 90 days of diagnosis. They then compared the outcomes of people who received allo-HCT in the first remission versus those who did not.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form